Inside Health Policy: Advocacy Groups Push ICER To Reevaluate Migraine Drug Analysis


Policy and patient advocacy groups are calling on the Institute for Clinical and Economic Review to rerun its analysis on the cost-effectiveness of three drugs to treat acute migraines, using ICER’s updated framework that considers societal factors. The advocacy groups expect the cost-effectiveness rating of the three drugs would increase further using that framework.